Related by context. All words. (Click for frequent words.) 79 pharmacokinetic properties 72 tolerability profile 71 antiviral activity 70 pharmacokinetic profile 70 neuroprotective properties 68 ENMD # 68 antiviral potency 68 retapamulin 68 vivo efficacy 68 pharmacokinetic profiles 68 favorable pharmacokinetic profile 68 orally bioavailable 67 antitumor activity 67 pharmacodynamic profile 67 pharmacodynamic properties 67 vivo potency 67 potent antiviral 66 oral prodrug 66 anticancer activity 66 TG# [003] 66 antiviral efficacy 66 bioavailability 65 Interferon alpha 65 bactericidal activity 65 CCX# 65 CGEN # 65 GLYX 65 Preclinical studies 65 tolerability profiles 65 antitumor efficacy 64 potent antitumor activity 64 calcitonin 64 bronchodilation 64 pharmacokinetic characteristics 64 nanomolar 64 GHRH 64 anti leukemic 64 tolerability 64 CaPre TM 64 LT NS# 64 Sym# 64 favorable pharmacokinetic 64 pharmacokinetic 64 preclinical efficacy 64 Traficet EN 63 DXL# 63 systemically administered 63 xenograft models 63 vidofludimus 63 INCB# [001] 63 favorable tolerability 63 nanomolar range 63 ISIS # 63 antitumor effects 63 delafloxacin 63 biodistribution 63 pomalidomide 63 administered subcutaneously 63 Zysolin TM 63 pharmacokinetic PK profile 63 rFIXFc 63 DACH platinum 63 Guanilib 63 polymerase inhibitor 63 #ME# 63 ProSavin 63 mTOR inhibitors 63 rHuPH# 63 anti amnesic 63 S/GSK# 62 HCV protease inhibitors 62 TRIOLEX 62 MEK inhibitors 62 riociguat 62 systemic absorption 62 CYT# 62 NGX# 62 preclinically 62 Serdaxin 62 Azedra 62 vitro potency 62 teriflunomide 62 receptor inhibitor 62 Belerofon 62 Carfilzomib 62 ganetespib 62 cytochrome P# #A# 62 PRTX 62 BAL# [001] 62 Tyrima 62 Symadex 62 radezolid 62 vitro cytotoxicity 62 R#/MEM # 62 cytoprotective 62 ocular formulation 62 antitumor 62 interferon IFN 62 IFN beta 62 maximally tolerated dose 61 orally dosed 61 Xanafide 61 antiangiogenic activity 61 Triolex 61 OHR/AVR# 61 parathyroid hormone PTH 61 oral formulation 61 ORMD 61 cMET 61 decitabine 61 BAL# [002] 61 antisense inhibition 61 inhibited tumor 61 pharmacokinetics 61 PRT# 61 immune modulating 61 liposomal formulation 61 Valortim ® 61 HuMax CD# 61 partial agonist 61 PSN# [002] 61 preclinical studies 61 nucleoside analog 61 systemic bioavailability 61 GFT# 61 CG# [003] 61 PEGylated 61 dose proportionality 61 RDEA# 61 anti angiogenic 61 CA4P 61 effector functions 61 potent inhibition 61 inhaled iloprost 61 Relivar 61 NEUGENE 61 GAP #B# 61 Onconase 61 dosage regimens 61 anti angiogenic agent 61 selective agonist 61 dosing regimens 61 PDE7 inhibitors 61 oral dosing 61 microglial activation 61 oral FTY# 61 SERMs 61 ciclesonide 61 cellular uptake 61 pro apoptotic 61 EZN 61 Seliciclib 60 nanomolar potency 60 Vidofludimus 60 NXL# 60 amprenavir 60 tezampanel 60 fosamprenavir 60 histone deacetylase inhibitor 60 steroid dexamethasone 60 dosing frequency 60 pan HDAC inhibitor 60 analgesic efficacy 60 cleavable linker 60 APOPTONE 60 zileuton 60 dose proportional pharmacokinetics 60 Zoraxel 60 pharmacokinetic parameters 60 alagebrium 60 selective inhibition 60 tipifarnib 60 Dasatinib 60 Granulocyte Colony Stimulating Factor 60 fluoroquinolone antibiotic 60 nanomolar concentrations 60 ARIKACE 60 potent antitumor 60 immunogenicity 60 oral JAK1 60 anti proliferative 60 pharmacokinetic interactions 60 pharmacodynamic PD 60 MEK inhibitor 60 inhibitory activity 60 PDE4 inhibitor 60 cannabinor 60 demonstrated antitumor activity 60 Anticalins ® 60 inhibitory effects 60 selectively inhibits 60 TRAIL R2 60 JAK inhibitor 60 OXi# 60 macrolide antibiotic 60 YONDELIS 60 VDAs 60 viral titers 60 huN# DM1 60 teduglutide 60 NEUGENE antisense 60 plasma kallikrein inhibitor 60 novel peptide 60 iroxanadine 60 SGS# 60 posaconazole 60 Panzem 60 solithromycin 60 XmAb# 60 RGB # 60 LY# [003] 60 IFN alpha 60 Lixivaptan 60 VA# [002] 60 nucleoside analogs 60 SCH # 60 antidepressant efficacy 60 low dose ritonavir 60 apremilast 60 intranasal delivery 60 IFN α 60 Solulin 60 combinability 60 tumorigenicity 60 ritonavir boosted 60 IDX# 60 diabetic neuropathic pain 60 Archexin 60 EndoTAG TM -1 60 echinocandin 60 preclinical models 60 Aclidinium 60 inecalcitol 60 nonclinical studies 60 highly immunogenic 60 PI3K inhibitor 60 #HT#A 60 intranasal formulation 60 immune stimulatory 60 neurotoxicity 60 immunomodulatory therapy 60 ATL/TV# 60 HIF PHI 59 Bezielle 59 metaglidasen 59 TRV# [001] 59 potency selectivity 59 IFN Beta 59 resolvin 59 Anidulafungin 59 Valortim 59 dexamethasone Decadron 59 nitazoxanide 59 NexACT 59 active metabolite 59 Apoptone 59 omega interferon 59 PXD# 59 interferon beta 59 bevirimat 59 pharmacodynamic 59 serum concentrations 59 PCK# 59 Preclinical studies suggest 59 CDK inhibitor 59 cynomolgus monkeys 59 caspofungin 59 milatuzumab 59 Epanova 59 RSD# 59 adipiplon 59 vitro studies 59 immunomodulator 59 ApoA1 59 mertansine 59 Posiphen 59 enzyme inhibitor 59 synthase TS 59 Rebif ® 59 HCV replicon 59 selective modulator 59 CIMZIA ™ 59 protein kinase inhibitor 59 AMPAKINE 59 granisetron 59 flavopiridol 59 transgene expression 59 iSONEP 59 lanthanum carbonate 59 efficacy 59 amrubicin 59 pegylated 59 immunomodulation 59 uricase 59 antiproliferative activity 59 dose cohorts 59 PEG SN# 59 BioVant 59 MetAP2 59 anticancer agent 59 subcutaneously injected 59 Aurora kinase 59 CLORETAZINE TM VNP#M 59 ZFN modified 59 pharmacodynamic profiles 59 HCV protease 59 dosed orally 59 CCR9 antagonist 59 entinostat 59 Abeta# 59 vascular disrupting agent 59 novel histone deacetylase 59 Aliskiren 59 inhibitory effect 59 CCR2 59 vivo validation 59 serum phosphate levels 59 pharmacokinetic PK 59 cardiac toxicity 59 cytotoxicity 59 complete cytogenetic response 59 aqueous solubility 59 forodesine 59 lomitapide 59 somatostatin 59 antitumor effect 59 hour bronchodilation 59 effector function 59 RNA antagonist 59 adenoviral 59 NOX E# 59 glycosylation profile 59 INCB# [003] 59 Androxal TM 59 acetylcholinesterase 59 eltrombopag 59 trodusquemine 59 Darinaparsin 59 Hsp# inhibitors 59 LSI #P 59 oral antiviral 59 ANAVEX #-# [001] 59 fosbretabulin 59 BNC# 59 Prodarsan ® 59 SRT# [003] 59 OMNARIS HFA 59 AEG# 59 binding affinity 59 axitinib 59 Cethromycin 59 muscarinic 59 #mg dose [001] 59 polymerase inhibitors 59 #D#C# 59 DuraSite 59 Tasimelteon 58 Factor VIIa 58 Tezampanel 58 minocycline 58 nanoviricides 58 Anticalins 58 fluticasone furoate 58 Lisofylline LSF 58 urocortin 2 58 DAVANAT 58 intracellular uptake 58 prucalopride 58 tumor regressions 58 Tamibarotene 58 INCB# [002] 58 erythropoietic 58 gastrointestinal motility 58 rBChE 58 Eg5 58 tiotropium bromide 58 vitro experiments 58 davunetide intranasal AL 58 depsipeptide 58 Rasagiline 58 busulfan 58 plasma concentrations 58 pathophysiological effects 58 CTAP# Capsules 58 selegiline 58 pramipexole 58 proteasome inhibitor 58 CCR5 antagonist 58 neuroprotective effects 58 gamma tocotrienol 58 antisense compounds 58 VAPRISOL 58 VELCADE melphalan 58 bioactivity 58 viral kinetics 58 CIMZIA TM 58 mGluR5 antagonists 58 OMP #M# 58 CRLX# 58 mGluR2 NAM 58 non steroidal 58 ZYBRESTAT 58 mouse xenograft models 58 Etoposide 58 Thiovir 58 Pharmacokinetic studies 58 AAG geldanamycin analog 58 neurotrophic 58 JAK inhibitors 58 Phase Ib clinical 58 octreotide acetate 58 plasma triglycerides 58 PROMACTA 58 Phase 2a trial 58 ESBA# 58 airway hyper responsiveness 58 IGFBP 3 58 5 HT2C receptor 58 CORT # 58 nelfinavir 58 Panzem R 58 Anticalin ® 58 acting muscarinic antagonist 58 immunostimulatory effects 58 ulimorelin 58 GnRH antagonist 58 pharmacokinetic studies 58 Sitagliptin 58 selective antagonist 58 non nucleoside 58 BMS# 58 ara C 58 safinamide 58 INT# [002] 58 acromegalic patients 58 dexpramipexole 58 CANCIDAS 58 indibulin 58 tumor regression 58 Cyclosporine 58 HQK 58 bactericidal 58 Pimavanserin 58 immunomodulatory effects 58 Durezol 58 ULORIC 58 DR Cysteamine 58 pharmacodynamic effects 58 Ophena TM 58 PBMCs 58 eosinophil count 58 viral suppression 58 orally administered inhibitor 58 elvitegravir 58 Phase Ib study 58 renal toxicity 58 IL #E 58 nucleotide analog 58 prostanoid 58 immunomodulatory 58 MP4OX 58 active moiety 58 antifibrotic 58 oxazolidinone 58 miconazole 58 vorinostat 58 Aplidin 58 mecamylamine 58 Gleevec resistant 58 LEP ETU 58 HGS# 58 Amplimexon 58 Octreolin 58 DCCR 58 ON #.Na 58 VEGF receptor 58 thalidomide Thalomid 58 GelVac TM 58 PS# [001] 58 Solorel TM 58 APTIVUS 58 betamethasone dipropionate 58 ceftazidime 58 RAPAFLO 58 hGH CTP 58 HuLuc# 58 HGS ETR2 58 chemotherapeutic drug 58 PLX cells 58 MabCampath 58 intravenous dosing 58 immunological responses 58 lopinavir 58 ProLindac 58 HIF PH inhibitors 58 Enhanze Technology 58 TriRima 58 Protelos 58 Blinatumomab 58 topical formulation 58 p# activation 58 ZD# [001] 58 tumor xenografts 58 DiLA2 liposomes 58 Orally administered 58 alfa interferon 58 prokinetic 58 ATL# [001] 58 exendin 4 58 fluvastatin 58 REP# 58 TNFalpha 58 integrase inhibitor 58 anti CD3 58 Anticalins R 58 AZILECT R 58 HCV replication 58 sulindac 58 Moxifloxacin 58 sublingual formulation 57 mcg dose 57 Mipomersen 57 sigma receptors 57 plasmin 57 BAY #-# 57 lymphocyte counts 57 prednisone prednisolone 57 triphendiol 57 antithrombotic 57 itraconazole 57 antidiabetic 57 USL# 57 angiogenesis inhibitor 57 hematological tumors 57 ACZ# 57 cidofovir 57 subcutaneously administered 57 menadione 57 ALGRX 57 PSMA ADC 57 Aurexis 57 NS#/#A protease 57 immunostimulatory 57 R baclofen 57 hA# 57 INGN 57 immune modulatory 57 dose ritonavir 57 glucagon receptor 57 visilizumab 57 indinavir 57 enzastaurin 57 docetaxel Taxotere ® 57 ospemifene 57 ARIKACE ™ 57 Phase 1b trial 57 eniluracil 57 chemopreventive agent 57 antiangiogenic 57 Cmax 57 vascular disrupting agents 57 RLY# 57 LHRH agonists 57 MTP inhibitor 57 erlotinib Tarceva ® 57 huC# DM4 57 Omacetaxine 57 cyclosporin 57 antiproliferative effects 57 PTP 1B 57 bicifadine 57 isotypes 57 PKC# 57 torezolid phosphate 57 nanopharmaceutical 57 azole 57 Phase IIA 57 salmeterol fluticasone 57 OXIGON TM 57 antigenicity 57 timolol 57 XP# Transported Prodrug 57 glucose lowering 57 efficacy tolerability 57 DU #b 57 alvespimycin 57 microsomes 57 insulin sensitizing 57 Ostarine 57 replicon 57 DDP# 57 Nanobodies 57 Factor IX 57 Synavive 57 APTIVUS r 57 ruxolitinib 57 Anthim 57 latanoprost 57 BRAF inhibitor 57 soluble CD# 57 ZYVOX 57 catalytic antioxidant 57 atacicept 57 ataluren 57 Omacetaxine mepesuccinate 57 ASONEP 57 DB# [003] 57 Debio 57 Tarvacin 57 NNRTIs 57 baminercept 57 rHuEPO 57 pegylated interferons 57 iobenguane 57 arbaclofen 57 RAPAFLO R 57 intermittent dosing 57 preclinical 57 DFMO 57 PD LID 57 bortezomib Velcade 57 TH# [003] 57 dose dependently 57 ADAGIO study 57 CEQ# 57 linear pharmacokinetics 57 Th1 type 57 Lactoferrin 57 Privigen 57 trabectedin 57 gonadotropins 57 receptor blocker 57 peripheral blood mononuclear 57 PDE4 inhibitors 57 TELINTRA 57 RhuDex ® 57 Milnacipran 57 non nucleoside HCV 57 SCIg 57 MGCD# [001] 57 cyclophilin inhibitor 57 JVRS 57 AVE# 57 neurotrophic factor 57 PPAR gamma agonists 57 Src inhibitors 57 antitumoral 57 Angiolix 57 potent inhibitor 57 subcutaneous formulation 57 XOMA 3AB 57 azacytidine 57 GLP1 agonist 57 rhIL 7 57 clinically meaningful efficacy 57 serum LDL cholesterol 57 systemic toxicity 57 factor G CSF 57 hyperphenylalaninemia HPA due 57 tanespimycin 57 MoxDuo ® IR 57 mapatumumab 57 bendamustine 57 galiximab 57 Bendavia 57 mu opioid receptor antagonist 57 CD#c 57 radiation sensitizer 57 deferasirox 57 adapalene 57 GAMMAGARD 57 Nanobody 57 Homspera 57 Th2 cytokines 57 PDGFR 57 potent antibacterial 57 MIRCERA 57 Civacir 57 virus HCV protease inhibitor 57 isatoribine 57 protease inhibitor PI 57 elotuzumab 57 racemic 57 ANG# 57 membrane permeability 57 #mg dose [002] 57 Pharmacokinetic 57 proteasome inhibitors 57 LY# [002] 57 potent antiproliferative 57 oral antidiabetic 57 MoxDuo 57 TRO# 57 highly selective inhibitor 57 nebulized formoterol fumarate 57 AEGR 57 circulating lymphocytes 57 novel VDA molecule 57 potently inhibited 57 Safinamide 57 vivo 57 beta lactam antibiotic 57 pharmacokinetics PK 57 interferon alfa 2b 57 pharmacokinetics pharmacodynamics 57 GLP toxicology studies 57 ibandronate 57 PROCHYMAL 57 dose dexamethasone 57 indomethacin 57 K ras mutations 57 beta interferons 57 Epothilones 57 Tarceva TM 57 generation purine nucleoside 57 alicaforsen enema 57 INVIRASE 57 Capesaris 57 isoproterenol 57 virological response 57 pyridostigmine 57 mg dose 57 MAP# 57 tafamidis 56 Iloperidone 56 immunomodulating 56 Nestorone 56 HuMax CD4 56 peptide antigens 56 tolvaptan 56 reversible inhibitor 56 concentration Cmax 56 Ventavis ® 56 methylnaltrexone 56 CorVue ™ 56 PEGylated anti 56 MGd 56 HCV protease inhibitor 56 ATD Gel 56 antisense inhibitors 56 N methyl 56 calcitriol 56 tigecycline 56 anti fibrotic 56 melphalan prednisone 56 investigational protease inhibitor 56 humanized anti 56 nucleotide analogs 56 IgG1 56 Anticalin R 56 CCR9 56 immunomodulatory properties 56 refractory gout 56 Erlotinib 56 injectable formulation 56 targeting CD# 56 Dapagliflozin 56 PTHrP 56 p# inhibitor 56 PF # [001] 56 Valdoxan 56 micafungin 56 conventional DMARDs 56 caspase inhibitors 56 Ampligen ® 56 Teriflunomide 56 TLR8 agonist 56 bexarotene 56 aclidinium 56 Oral NKTR 56 Nanobody ® 56 Neulasta ® 56 ELND# 56 5 HT6 receptor 56 μg ml 56 tipranavir 56 Laquinimod 56 PDE1 56 cardioprotective effects 56 bronchodilatory 56 mucociliary clearance 56 dosing regimen 56 virologic response 56 zafirlukast 56 anidulafungin 56 LAF# 56 mGluR5 NAM 56 Adenosine 56 Calcitonin 56 Zavesca R 56 JUVISTA R Human 56 interferon alfa 56 renin inhibitor 56 Losartan 56 potent inhibitors 56 TG# [001] 56 PSN# [001] 56 Tarvacin TM 56 alefacept 56 chlorambucil 56 cethromycin 56 pharmacodynamic parameters 56 PEGylated interferon beta 1a 56 LRAT 56 XL# inhibits 56 HuMax EGFr 56 echinocandins 56 relapsed MM 56 MGCD# [002] 56 NMDA antagonist 56 hemagglutination inhibition HAI 56 adrenocorticotropic hormone ACTH 56 dose cohort 56 monomeric 56 potent anti angiogenic 56 Plicera 56 ANAVEX #-# [003] 56 Intravail R 56 TRAIL R1 56 Inhalation Solution 56 immunogenic 56 inhibitor RG# 56 subcutaneous injections 56 neutralizing antibody 56 Vaxfectin R 56 intravenously administered 56 KNS # 56 volociximab 56 ZOLINZA 56 splice variants 56 norepinephrine reuptake inhibition 56 piperacillin tazobactam 56 pharmacodynamics 56 Serdolect ® 56 fumagillin nanoparticles 56 PPAR gamma agonist 56 antibody responses 56 IMiDs ® 56 solubilization 56 NKTR 56 coadministration 56 transdermal delivery 56 INC# 56 pilocarpine 56 TKM ApoB 56 plasma pharmacokinetics 56 lowers blood glucose 56 histone deacetylase HDAC inhibitor 56 p# biomarkers 56 overlapping toxicities 56 TLR8 56 deferiprone 56 immunotoxins 56 L asparaginase 56 HDAC inhibitor 56 somatostatin analogue 56 guanfacine 56 thymalfasin 56 administered orally 56 evaluating tivozanib 56 Exelixis compounds 56 antimicrobial efficacy 56 CBLC# 56 Actilon 56 CD# antibody [001] 56 neutrophil counts 56 telbivudine 56 fluticasone salmeterol 56 idraparinux 56 SNRI 56 teriparatide 56 Genz # 56 peripherally acting 56 oral gallium 56 Ganciclovir 56 immunoreactivity 56 locomotor activity 56 siRNAs targeting 56 PEGylated Fab fragment 56 ancrod 56 peptide conjugated 56 paclitaxel Taxol 56 pegylated interferon alfa 56 antiapoptotic 56 Tß4 56 lactate dehydrogenase 56 cytokine IL 56 Cellastim 56 fulvestrant 56 nanoviricide 56 alpha7 56 HE# [002] 56 antisense drug 56 TYGACIL 56 multitargeted 56 Androxal 56 sitaxsentan 56 GRN#L 56 pitavastatin 56 MUC1 56 H#N# VLP vaccine 56 salmon calcitonin 56 Golimumab 56 enzyme inhibition 56 PRX# 56 Phase 1a clinical 56 seliciclib 56 antiangiogenic agents 56 antiarrhythmic 56 lipid particles 56 IFN gamma 56 2 methoxyestradiol 56 Hyphanox 56 neointimal proliferation 56 CD# monoclonal antibody 56 EVIZON 56 ritonavir boosting 56 Lisofylline 56 JAK2 inhibitor 56 selective androgen receptor modulator 56 solubility 56 resolvins 56 serum cortisol 56 factor TNF 56 GRN# 56 AVN# [001] 56 glutamyl 56 B7 H3 56 potent anticancer 56 Bortezomib 56 investigational humanized monoclonal antibody 56 AP# [003] 56 PC# cells 56 PYY 56 proton pump inhibitor PPI 56 GLPG# 56 Natalizumab 56 somatostatin analog 56 CRx 56 Menerba 56 HSP# inhibitor 56 S1P antibody 56 IgG antibodies 56 retinoid 56 therapeutic monoclonal antibody 56 prostaglandin synthesis 56 masitinib 56 zoledronate 56 PDE# 56 ziconotide 56 vasodilatation 56 small molecule activators 56 IMA# 56 FTY# 56 relaxivity 56 tenofovir emtricitabine 56 Imprime PGG 56 plasma fibrinogen 56 tocilizumab 56 pro angiogenic 56 tau phosphorylation 56 transgenic rats 56 raltegravir 56 tapentadol ER 56 Cleviprex TM clevidipine 56 Pharmacokinetics PK 56 potently inhibit 56 RG# [001] 56 microsomal 56 eotaxin 56 PEG Interferon lambda 56 calcipotriene 56 HDAC EGFR 56 angiotensin analog 56 Multimeric 56 NMDA antagonists 56 dihydrochloride 56 injectable formulations 56 ibudilast 56 SNT MC# 56 serum calcium levels 55 urate lowering 55 GPx 55 Flt3 55 insulin degludec 55 selective inhibitor 55 NVA# 55 Lubiprostone 55 Pazopanib 55 Cloretazine R VNP#M 55 imatinib therapy 55 CINTREDEKIN BESUDOTOX 55 dasatinib Sprycel 55 LEXIVA r 55 VEGF inhibitors 55 growth hormone secretion 55 lenalidomide Revlimid R 55 HGS ETR1 mapatumumab 55 LPA1 receptor